Semax

Semax is a synthetic analog of ACTH(4-10), the fragment of adrenocorticotropic hormone responsible for nootropic activity. Unlike full-length ACTH, Semax lacks hormonal (corticotropic) effects while retaining neurotrophic properties.

The peptide upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression. It modulates serotonergic, dopaminergic, and cholinergic neurotransmitter systems, influencing cognitive processes including attention, learning, and memory.

Semax demonstrates neuroprotective effects in models of oxidative stress and ischemic injury. Research indicates it stabilizes enkephalins by inhibiting their enzymatic degradation, which may contribute to its anxiolytic and analgesic properties.

Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It is an analog of the ACTH(4-10) fragment with an added Pro-Gly-Pro C-terminal tripeptide to enhance metabolic stability.

Semax has been approved as a nootropic and neuroprotective agent in Russia and several CIS countries. It has been the subject of extensive preclinical and clinical research into cognitive function, neuroprotection, and neurodevelopmental processes.

Certificate of Analysis (COA) available upon request. Each batch is tested via HPLC for purity and Mass Spectrometry for identity confirmation.